©2018 by Novobind Livestock Therapeutics Inc.

Press Release

Blagnac (France) and Vancouver (Canada) July 1, 2019

 

 

Lallemand Animal Nutrition and NovoBind Announce Joint Development and Commercialization Agreement for Advanced Salmonella Biologics

 

 

Lallemand Animal Nutrition (“Lallemand”) and NovoBind Livestock Therapeutics Inc. ("NovoBind") are pleased to announce a strategic collaboration agreement.

 

The agreement comprises a multi-phase joint research and development program to scale-up global production and conduct in vivo trials of NovoBind’s Salmonella biologics (NBXs). NBXs are derived from camelid single domain anti-body fragments.

 

In addition to entering into the collaboration agreement, Lallemand is making a strategic minority equity investment into NovoBind. This investment forms part of NovoBind’s current Series A investment round.

 

Hamlet Abnousi, co-founder and CEO of NovoBind, commented, “We are absolutely delighted to have reached agreement for this collaboration with Lallemand. This represents a significant step in the validation and commercialization of our proprietary NBX technology.  NovoBind seeks to partner with global leaders in the animal health and animal feed sector to bring our technology to market, to improve the quality of food in the food chain, and to reduce wastage caused by bacteria, viruses  and parasites in aquatic and terrestrial livestock production. We also welcome Lallemand’s participation as a shareholder in NovoBind”.

 

Mathieu Castex, Research and Development Director of Lallemand Animal Nutrition said, “We are pleased to enter into this agreement with NovoBind which is part of our ongoing strategy to develop new technologies based on “solution specific microbial platforms” for animal nutrition and animal health applications. Our know-how and expertise in microbial development, production and registration will help accelerate the commercialization of NovoBind’s advanced Salmonella biologics solution”.

 

 

About NovoBind

 

NovoBind develops products that meet the growing global demand for increased food production without the use of antibiotics and antimicrobial chemicals. Their next-generation biologics target and neutralize devastating pathogenic bacteria, viruses, and parasites that cause $22 billion (USD) in aggregate annual loss to producers in the poultry, shrimp, and companion animal sectors. NBXs are naturally sourced, biologically produced, Non-GMOs, that specifically target and neutralize “bad actors”. NovoBind is currently expanding its technology platform to address other sectors of food production, including crop health.

 

 

About Lallemand Animal Nutrition

 

Lallemand Animal Nutrition is committed to optimizing animal performance and well-being with specific natural microbial product and service solutions. Using sound science, proven results and knowledge, Lallemand Animal Nutrition develops, produces and markets high value yeast and bacteria products─ including probiotics, forage inoculants and yeast derivatives. These innovative solutions positively benefit animal nutrition and well-being, forage management and animal environment. Lallemand offers a higher level of expertise, leadership and industry commitment with long-term and profitable solutions to move our partners Forward.

 

Contact and Media Enquiries:

For NovoBind:            

         

Hamlet Abnousi, CEO                                 

Email: info@novobind.com                      

Phone: 604-218-4594

www.novobind.com

 

For Lallemand Animal Nutrition:

 

Sylvie Roquefeuil, Communications Manager

Email: sroquefeuil@lallemand.com

Phone: +335 62 74 55 55

www.lallemandanimalnutrition.com

linkedin.png